Think Small, But Smart
Small molecules already represent the bulk of the contract manufacturing market and FDA approvals are on the up. For CMOs, this presents opportunities and challenges.
Matt Moorcroft |
Ten years ago, the pharma manufacturing industry looked very different; the age of the blockbuster drug had reached its zenith and sites across the US were being shut down, mothballed, or consolidated. Indeed, many believed the industry was heading to low-cost countries in Asia, lost forever from the West.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.